



**HAL**  
open science

## Adverse drug reactions in internal medicine units and associated risk factors

Juan Francisco Sánchez Muñoz-Torrero, Paloma Barquilla, Raul Velasco, Maria del Carmen Fernández Capitan, Nazaret Pacheco, Lucia Vicente, Jose Luis Chicón, Sara Trejo, Jose Zamorano, Alicia Lorenzo Hernandez

► **To cite this version:**

Juan Francisco Sánchez Muñoz-Torrero, Paloma Barquilla, Raul Velasco, Maria del Carmen Fernández Capitan, Nazaret Pacheco, et al.. Adverse drug reactions in internal medicine units and associated risk factors. *European Journal of Clinical Pharmacology*, Springer Verlag, 2010, 66 (12), pp.1257-1264. 10.1007/s00228-010-0866-6 . hal-00613747

**HAL Id: hal-00613747**

**<https://hal.archives-ouvertes.fr/hal-00613747>**

Submitted on 6 Aug 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



**Adverse drug reactions in Internal Medicine Units, and risk factors associated**

Journal:	<i>European Journal of Clinical Pharmacology</i>
Manuscript ID:	EJCP-2010-0140.R1
Type of submission:	Original
Date Submitted by the Author:	12-Jun-2010
Complete List of Authors:	Sánchez Muñoz-Torrero, Juan Francisco; H.San Pedro Alcántara, Internal Medicine Barquilla, Paloma; H. San Pedro Alcantara, Internal Medicine Velasco, Raul; H. San Pedro Alcantara, Internal Medicine Fernandez Capitan, Maria del Carmen; H. La Paz, Internal Medicine Pacheco, Nararet; H. San Pedro Alcantara, Internal Medicine Vicente, Lucia; H. San Pedro Alcantara, Internal Medicine Chicón, Jose Luis; H. San Pedro Alcantara, Internal Medicine Trejo, Sara; H. San Pedro Alcantara, Internal Medicine Zamorano, Jose; H. San Pedro de Alcantara, Unidad Investigacion Lorenzo Hernandez, Alicia; H. La Paz, Internal Medicine

1  
2  
3 **Adverse drug reactions in Internal Medicine Units, and risk**  
4 **factors associated.**  
5  
6

7 **Juan Fco Sánchez Muñoz-Torrero. MD, PhD.**

8 **Paloma Barquilla. MD..**

9 **Raul Velasco. MD.**

10 **Carmen Fernández Capitan\*. MD, PhD**

11 **Nazaret Pacheco. MD.**

12 **Lucia Vicente. MD.**

13 **Jose Luis Chicón. MD.**

14 **Sara Trejo. MD.**

15 **Jose Zamorano. Ph.D.**

16 **Alicia Lorenzo Hernandez\*. MD.**

17 **Servicios de Medicina Interna Hospital San Pedro de Alcantara. (Cáceres) and,**  
18 **Hospital La Paz. (Madrid)\***  
19  
20  
21  
22  
23  
24

25 **Keywords:** Adverse drug reactions, incidence, risk factors.

26 **Word count (abstract) :** 243

27 **Word count article (excluding abstract, references, tables) :** 2454  
28  
29  
30  
31  
32

33 **Correspondence should be addressed to:**

34 **Juan Fco Sánchez Muñoz-Torrero, MD, Ph D**

35 **Servicio de Medicina Interna**

36 **Hospital San Pedro de Alcantara.**

37 **10004 Cáceres. Spain**

38 **e-mail: [juanf.sanchezm@gmail.com](mailto:juanf.sanchezm@gmail.com)**  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **Abstract. Objectives:** This study was designed to assess the prevalence of adverse drug  
5 reactions (ADRs) in Internal Medicine wards of two teaching Hospitals, identify the most  
6 common ADRs, principal medications involved and, determine the risk factors implicated in the  
7 appearance of such ADRs. **Methods:** All admissions over 10-weeks were followed  
8 prospectively using an intensive drug surveillance method to identify ADRs. Clinical, laboratory  
9 data, drug prescribed and ADRs were taken into consideration. Status of nutrition, liver and  
10 kidney function at admission and ADRs time were determined. In order to assess drugs  
11 interaction a software package was used. **Results:** A total of 405 patients were evaluated, 126  
12 patients (31%) had 128 ADRs, 122 ADRs occurred during hospitalization. Two ADRs-related  
13 deaths were observed during the study. Reactions affecting the gastrointestinal tract, skin and  
14 haematological system were among the most frequently ADRs. For ADRs observed during  
15 admission predictors of its occurrence in a multivariable regression model were: OR (95% CI);  
16 more 12-days hospitalization: 2.11(1.27-3.47), any drug interaction: 9.33 (5.12-17) and acute  
17 change estimated glomerular filtration rate over admission > 20%: 2.46(1.45-4.2). Worsening of  
18 renal function or drug interaction was observed in nine of ten ADRs. Age, sex, nutrition and  
19 number of drugs used were not related with ADRs. **Conclusion:** A significant prevalence of  
20 ADRs was found among hospitalized patients. Duration of hospital admission, changes in renal  
21 status during hospitalization and drugs interaction seem to be important risk factors to ADRs.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction.

Adverse drug reactions (ADRs) are a major cause of morbidity and pose a substantial burden on healthcare resources<sup>1</sup>. Detection of adverse drug reactions in hospitals provides an important measure of the burden of drug-related morbidity on the healthcare system. Epidemiological research shows an incidence of ADRs in 10-13 % of all hospitalized patients<sup>1-3</sup>. These data remain clinically relevant because a significant proportion of ADRs are life-threatening or fatal ADRs, rank fourth to sixth in leading causes of death<sup>4,5</sup>. Because up to 50% of ADR are preventable more attention to their detection and management is warranted<sup>6,7</sup>.

Previous studies explored magnitude, nature and prevalence of ADRs. Common factors associated with ADRs are age, sex, number of drugs or comorbidities<sup>5-10</sup>. Meanwhile, other important factors such as renal function or pharmacologic counteractions, have not been well studied<sup>1-12</sup>. Patients hospitalized in Internal Medicine wards have predisposition of suffering ADRs because they are older, have several comorbidities, and need multiple drugs at hospitalization. So patients hospitalized at Internal Medicine wards stand for an interesting population for studying ADRs<sup>11</sup>. Frequently these patients have renal insufficiency that can worsen during hospitalization because of the disease or condition that is causing the hospitalization. The different interactions between drugs could be also an important issue in the apparition of ADRS<sup>12</sup>. Due to the complexity of treatments and the large number of drugs required, the clinician may not consider the interactions between drugs in daily practice. Recently several software packages have shown useful for analyzing drug prescription that can be useful for predicting drug interactions and so, adjusting treatments easier<sup>12,13</sup>.

The aim of this study was to describe the most common clinical manifestations and drugs frequently responsible for ADRS and, to identify in patients who had ADRs while they were hospitalized in internal medicine independent factors predictive of these ADRS including drug interaction and acute changes in renal function.

1  
2  
3  
4 **PATIENTS AND METHODS.** This prospective observational study included all patients  
5 admitted in two General Internal Medicine wards of 2 Docents Hospitals , San Pedro de  
6 Alcantara (Cáceres) and La Paz (Madrid) in Spain, over a period of 10 consecutive weeks from  
7  
8 1 September 2009 to 14 November 2009. For detection and evaluation of potential ADRS all  
9  
10 admissions underwent daily intensive pharmacovigilance by at minimum three physicians (1  
11  
12 staff physician and 2 residents in training). **Classification of adverse drug reactions.** The  
13  
14 classification proposed by Rawlins and Thompson<sup>14</sup> was used to establish the potential for  
15  
16 predicting suspected adverse reactions. The algorithm of Naranjo<sup>15</sup> and co-workers was used to  
17  
18 establish the causality between the drug and the suspected adverse reaction. ADR was  
19  
20 considered if it was definitive or probable. Data were collected using a specific data collection  
21  
22 sheet developed for this investigation. For all patients, information regarding age, sex, weight  
23  
24 and tall, duration of hospital stay, all diagnosis at discharge was collected, as well as amounts  
25  
26 and brand names of medicines taken in the previous month, during the hospitalization, including  
27  
28 self –medication. Blood test for creatinina, ALT, AST, alkaline fosfatase and filtration glomerular  
29  
30 rate (estimated by Cockcroft-Gault formula:  $GFR(ml/min) = (140 - \text{age}(y)) \times \text{body weight}(kg) / 72 \times$   
31  
32 serum creatinine (mg/dl); in female  $\times 0.85$  ) were determinate at entry and the day of detection  
33  
34 of ADRs. Patients were then classified into (Group 1) patients without ADR, (Group 2) patients  
35  
36 admitted because of ADR or detected during hospitalization.

37  
38  
39  
40  
41  
42  
43 The possible interactions between drugs were evaluated using Lexi-Interact™ Online (Lexi-  
44  
45 Comp, Inc. Ohio)<sup>16</sup>. This is a comprehensive Drug-to-Drug Interaction Analysis Program with a  
46  
47 Rapid indicator to show the interaction data. This program also assigned a risk rating of A, B, C,  
48  
49 D, or X. The progression from A to X is accompanied by increased urgency for responding to  
50  
51 the data. In general, A and B monographs are of academic, but not clinical concern.  
52  
53 Monographs rated C, D, or X always requires the user's attention. The definition of each risk  
54  
55 rating is as follows: *A: No Known Interaction, B: Data demonstrate that the specified agents*  
56  
57 *may interact with each other, but there is little to no evidence of clinical concern resulting from*  
58  
59 *their concomitant use. No Action Needed. C: Data demonstrate that the specified agents may*  
60

1  
2  
3 interact with each other in a clinically significant manner. The benefits of concomitant use of  
4 these two medications usually outweigh the risks. An appropriate monitoring plan should be  
5 implemented to identify potential negative effects. Dosage adjustments of one or both agents  
6 may be needed in a minority of patients. *Monitor Therapy. D:* Data demonstrate that the two  
7 medications may interact with each other in a clinically significant manner. A patient-specific  
8 assessment must be conducted to determine whether the benefits of concomitant therapy  
9 outweigh the risks. Specific actions must be taken in order to realize the benefits and/or  
10 minimize the toxicity resulting from concomitant use of the agents. These actions may include  
11 aggressive monitoring, empiric dosage changes, choosing alternative agents. *Consider Therapy*  
12 *Modification. X:* Data demonstrate that the specified agents may interact with each other in a  
13 clinically significant manner. The risks associated with concomitant use of these agents usually  
14 outweigh the benefits. These agents are generally considered contraindicated. *Avoid*  
15 *Combination.* The severity of ADRS was defined as: Minor (effects would be considered  
16 tolerable; in most cases no need for medical intervention); Moderate (medical intervention  
17 needed to treat effects; effects do not meet criteria for Major); and Major (effects may result in  
18 death, hospitalization, permanent injury, or therapeutic failure). We also collected about the  
19 need of prolong hospitalization and the drug interaction itself as the cause of hospitalization.

20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41 **Data analysis.** All the data were expressed as the mean±SD or percentage. The differences in  
42 the values of the variables between the start and the end of the 10 –weeks treatment period  
43 were calculated as percent changes, values at the end of 12 week’s treatment minus those at  
44 the start of the treatment x 100/the value at the start of the treatment. Patients who were  
45 hospitalized because of ADRS were excluded for the study of potential factors associated with  
46 ADRS. The Chi-square test and Student’s t-test for independent samples were used to assess  
47 the statistical significance between ratios and means, respectively. In order to control potential  
48 confounding factors and to determine independent association between ADRS and risk factors  
49 for ADRS, the logistic regression analysis was employed. Factors demonstrating significant  
50 association with an ADR were included in the multivariable logistic regression model. Since  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 other researchers had identified sex and age as risk factors for an ADR, these variables were  
4 included in the model without considering the statistical significance of the univariate analysis. A  
5  
6  
7  
8 p value lower to 0.05 was considered statistically significant. Data analysis was performed using  
9  
10 the SPSS software package (SPSS Inc., Chicago, Illinois, USA).

11  
12 **Results:** During a 10-weeks study period in two university hospitals, 405 patients were  
13  
14 intensively monitored with respect to ADRs. (Fig.1). There were 128 adverse reactions in 126  
15  
16 (31%) patients. In 24 patients the ADRs was the cause of hospitalization and 102 patients  
17  
18 suffered ADRs during the hospitalization in internal medicine ward. The ADRs were moderate in  
19  
20 93 (73%), major in 22 (17%) and were fatal in 2 patients (1, 6%).

21  
22 Table 1 shows main characteristics of patients in the study. There were no significant  
23  
24 differences between the group of ADRs and non ADRs in age, sex and BMI. Number of  
25  
26 diagnoses of each patient was bigger in patients with ADRs:  $2, 3 \pm 1.2$  vs.  $2.0 \pm 1.1$ . ADRs  
27  
28 patients have more lung diseases (35% vs. 25%,  $p < 0.05$ ) and diabetes than controls (35% vs.  
29  
30 20%,  $p < 0.001$ ). An important difference was the duration of hospitalization that was longer for  
31  
32 ADRs patients:  $18 \pm 17$  days vs.  $9.6 \pm 5.8$ ,  $p < 0.001$ . Time from hospitalization to ADRs was  
33  
34  $4.3 \pm 3.9$  days.

35  
36 Table 2 shows the drugs causing the different ADRs. 28 patients suffered from diarrhea  
37  
38 because of antibiotic use. The second most frequent ADRs was bleeding, because of  
39  
40 acenocumarol or enoxaparin (15 patients). The third frequent ADRs was rash (9 patients),  
41  
42 although cutaneous involvement was the ADRs in 20 patients, mainly due to some antibiotics  
43  
44 but also fenitoin and atorvastatin.

45  
46 Among patients who had ADRs during admission, (were excluded from analysis those  
47  
48 hospitalized for this reason), factors associated with the aparition of ADRs were analyzed and  
49  
50 showed in table 3. Renal function and drug-drug interaction were staisically significative ( $p <$   
51  
52  $0.001$ ). Elevated serum creatinine at hospitalization was significantly higher in patients at ADRs  
53  
54 than more high in control group during hospitalization (mg/dL):  $2.02 \pm 1.22$  vs  $1.72 \pm 0.95$ . A  
55  
56 filtration glomerular rate below of 60 ml/min was observed in 41% of patients with ADRs vs 22%  
57  
58  
59  
60



1  
2  
3 in control. A decreased of filtration glomerular rate of 20% respect a baseline during  
4 hospitalization appeared in 35% of case patients and 18% of controls ( $p < 0.001$ ). Possible  
5 interaction between drugs was analyzed by an electronic device and were found in 84%  
6 patients with ADRs vs. 36% controls ( $p < 0.0001$ ) Drugs causing interactions were metabolized  
7 mainly by cytochrome P 450 2C9 (drugs behave as inhibitors and substrates), 3A4 (inducers)  
8 and 2D6 (substrates). Interaction between three or more drugs appeared in 35% of ADRs  
9 patients and 15% controls ( $p < 0.001$ ). We judged as cause ADRs: 41 drugs interaction,  
10 decrease in renal function in 28 patients, and 17 possible influence of both. The Drug  
11 interactions are most likely involved were: 21 patients cytochrome P 450 (2C9), 8 (3A4),  
12 6(2D6), 4(1A2), 1(2C9) and 1 (2C19).  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25  
26 In the logistic regression analysis to analyze factors associated with ADRs we found (as shown  
27 in table 4): the duration of hospitalization ( $p < 0.001$ ), change of 20% of filtration glomerular rate  
28 ( $p < 0.001$ ) and any drug interaction were associated with ADR ( $p < 0.0001$ ).  
29  
30  
31  
32  
33  
34

#### 35 Discussion:

36  
37 The most common ADRs in hospitalized patients and factors associated were analyzed  
38 in this study. Diarrhea postantibiotic, bleeding due to antithrombotic therapy and rash were the  
39 most frequent ADRs observed. Conditions associated with ADRs during hospitalization were  
40 prolonged hospitalization, acute change in filtration glomerular rate and drug interaction. Other  
41 previously cited as risk factors, like age, sex and number of drugs used were not related with  
42 ADRs in our study.  
43  
44  
45  
46  
47  
48  
49

50 The frequency of ADRs in hospitals varies greatly between different published studies<sup>2-4</sup>, which  
51 can be explained by differences in their methods of identifying ADRs, the definition of adverse  
52 reactions, the methodology used for their detection, the complexity level of the pathologies  
53 under treatment and the severity of the reaction, among others<sup>5,8,9,11,12,17-19</sup>. The rate of ADRs  
54 found in this study -31%- was higher than the average of 6.7% (range 1.2-24%) found in  
55 previous studies<sup>2-4</sup> but consistent with other reports<sup>20,21</sup> using, like us, the "gold standard of  
56  
57  
58  
59  
60

1  
2  
3 pharmacovigilance”, intensive prospective ADRs detection<sup>20-21</sup>. Drugs causing ADRs<sup>23</sup> were  
4 similar to those described by other authors<sup>16,21,23</sup> where cardiovascular drugs, anticoagulants  
5 and antibiotics were most frequently associated with ADRs. Reactions affecting the  
6 gastrointestinal tract, skin, mucosa and haematological system are among the most frequently  
7 observed events. The ADRs are in relation with drugs used for managing frequently disease of  
8 patients admitted in Internal Medicine wards.

9  
10 Previous studies have examined many potential risk factors associated with ADRs in a variety of  
11 settings<sup>5,7,10</sup>. Conditions often cited as potential risk factors of ADRs are increasing age, sex,  
12 large numbers of prescribed drugs in individual patients or length of hospitalisation<sup>5-10</sup>. Failure  
13 of dose adjustment in patients with impaired renal function and, drug-drug interactions also  
14 were as important predictors of ADRs<sup>10-12</sup>. Studies in the field of pharmacovigilance using  
15 multiple regression models are rare and, we unknown what variables were independent ADR  
16 predictors<sup>20</sup>. There is consensus about the predictive power of large numbers of prescribed  
17 drugs –more than four- as an independent predictor of ADRs<sup>6,8,20</sup>. In our analysis, number of  
18 drug interactions were one of the most important factors associated with apparition of ADRs, but  
19 not the number of drugs itself. We found a high rate of medication use with interaction by  
20 cytochrome P450 2C9,2D6 and 3A4. These cytochrome frequently are implicate in metabolism of  
21 common drugs<sup>25</sup>. Nowadays, complexity of treatments make difficult to know the possibility of  
22 apparition of interactions between two or more drugs, so adequate software package<sup>25-27</sup> will be  
23 useful in this way. Most studies summarized that 69% of adverse events as preventable<sup>7,23</sup> and  
24 can therefore be considered to result from medication errors. Although they are several  
25 recommendations about using electronic devices, their use have not been generalized and  
26 electronic devices have several problems that have to be removed<sup>25,27</sup>. We suggest checking  
27 drug interactions on a software package, or assess the cytochrome involve in metabolism of  
28 drugs most frequently .

29  
30 Other common problem that has not been previously well studied is renal function as cause of  
31 ADRS<sup>27,30</sup>. We report an elevated incidence of renal dysfunction measured as having

1  
2  
3 glomerular filtration rate below 60 ml/min, 41% in ADRS patients vs 22% controls. Also we  
4  
5 observe a worsening of renal function during hospitalization, renal function drop >20% in 35% of  
6  
7 case vs 18% controls. This important prevalence of renal impairment was clearly different from  
8  
9 reported by others <sup>27</sup>. Dose adjustment with renal function probably would have prevented the  
10  
11 apparition of several ADRs. Although, we can observe ADRs before identify the changes in  
12  
13 renal function, prevent dose titration. Sex, age and malnutrition were also correlated with the  
14  
15 presence of ADRs in literature reports <sup>5-10</sup>. However, in our population, neither albumin, sex or  
16  
17 increasing age were independent ADR predictors. In summary, acute changes in renal function  
18  
19 or drug interactions were observed in 88% of patients suffering ADRs. Therefore we suggest  
20  
21 that drug doses adjustment for renal function and assess interactions could be preventable a  
22  
23 great number of ADRs in clinical practice.  
24  
25  
26

27  
28 In terms of pharmacoeconomy it was calculated that cost of hospitalization of patient with  
29  
30 ADRs could be about two thousand of million dollars per year in the United States<sup>30</sup>. It is  
31  
32 estimated that patients who had an adverse drug reaction, the duration of hospitalization was  
33  
34 prolonged by 4,3 days compared with patients who did not experience an adverse drug reaction  
35  
36 leading to an increase in costs for each episode of hospitalization. In the present study, length  
37  
38 of hospitalization was greater for ADRS (18 vs 9,6 days). We can't analyze if a longer duration  
39  
40 was the cause or the consequence of ADRs. However, the fact that ADRs appeared in the 5  
41  
42 day of hospitalization in most cases, shows that ADRs can be one of the main causes of a  
43  
44 longer duration of being hospitalized for ADRs patients.  
45  
46  
47

48  
49 The study have some limitations. Probably the most important is the fact that we couldn't  
50  
51 analyzed specifically the factor implicated in ADRs in each particular case. Despite using a  
52  
53 multiple regression model, a definitive discrimination between causative or confounding factors  
54  
55 in predicting an ADR is difficulty. We can not judge if renal failure was cause or effect of ADRs  
56  
57 in all situations. Also, we only analysed pharmacokinetic and no pharmacodynamic interactions  
58  
59 due of program used. However, renal insufficiency or drug interaction were implicated in nine of  
60

1  
2  
3 ten ADRs, so we have to consider these two mechanisms as very important factors contributing  
4 to ADRs development. Studies with a longer period of observation and more hospitals  
5 implicated in the study of ADRs would help to determine the significance of these mechanisms  
6 in ADRs or identifying more factors implicated.  
7  
8  
9

10  
11  
12 In summary, we believe that the present study makes important contributions. First, the real  
13 incidence of ADRs in Internal Medicine could have been infraestimated. Second, acute renal  
14 function worsening during hospitalization, prior renal dysfunction and drug interactions seem to  
15 be important factors contributing to ADRs appearance.  
16  
17  
18  
19  
20  
21

## 22 23 24 25 26 27 **References:**

- 28 1. Kohn LT, Corrigan JM, Donaldson MS, Editors. Institute of Medicine. To error is human:  
29 building a safer health system. Washington, DC. National Academies Press, 2000
- 30 2. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reaction. *BMJ*  
31 1998; 316: 1295-1298.
- 32 3. Davies EC, Green CF, Mottram DR, Pirmohamed M. Adverse drug reactions in hospitals: a  
33 narrative review. *Curr Drug Saf.* 2007;2:79-87.
- 34 4. Trontell A. Expecting the unexpected: drug safety, pharmacovigilance, and the prepared mind.  
35 *N Engl J Med* 2004; 351: 1385-7.
- 36 5. Talley RB, Laventurier MF. Drug-induced illness. *JAMA* 1975; 229:1043-1048
- 37 6. Lagnaoui R, Moore N, Fach J et als. Adverse drug reactions in a department of systemic  
38 diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. *Eur J*  
39 *Clin Pharmacol.* 2000 ;56:181-6.
- 40 7. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug  
41 reactions. *Ann Pharmacother.* 2002;36:1331-6.
- 42 8. Klein U, Klein M, Sturm H, et als. The frequency of adverse drug reactions as dependent  
43 upon age, sex and duration of hospitalization. *Int J Clin Pharmacol Biopharm.* 1976;13:187-95.
- 44 9. Martin RM, Biswas PN, Freemantle SN, et als Age and sex distribution of suspected adverse  
45 drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort  
46 studies. *Br J Clin Pharmacol.* 1998;46:505-11.
- 47 10. Zopf Y, Rabe C, Neubert A, Janson C, Brune K, Hahn EG, Dormann H.  
48 Gender-based differences in drug prescription: relation to adverse drug reactions.
- 49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Pharmacology. 2009;84:333-9.

4 11. Krähenbühl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krähenbühl S.  
5 Drug-related problems in hospitals: a review of the recent literature. *Drug Saf.* 2007;30:379-407.

6 12. Schein JR. Epidemiology, outcomes research, and drug interactions  
7  
8 *Drug Metabol Drug Interact.* 1998;14:147-58.

9  
10 13. Kuperman GJ, Bobb A, Payne TH, et als. Medication-related clinical decision support in  
11 computerized provider order entry systems: a review. *J Am Med Inform Assoc.* 2007;14: 29-40.

12 14. Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM, ed.  
13 *Textbook of adverse drug reactions.* Oxford: Oxford University Press, 1991: 18-45

14 15. Naranjo CA, Busto U Sellers EM, et al. A method for estimating the probability of adverse  
15 drug reactions. *Clinical Pharmacology and Therapeutics* 1981; 30: 239–245.

16 16. Lexi-Comp. Drug interactions handbook, and drug interactions software.  
17 <http://www.lexi.com/web/index.jsp>.(Accessed June 10, 2010)

18 17. Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. *Drug*  
19 *Saf.* 2006;29:385-96.

20 18. Lazarou J. Pomeranz BH. Corey PN. A Meta-analysis of Prospective Studies Incidence of  
21 Adverse Drug Reactions in Hospitalized. *JAMA* 1998;279:1200-1205.

22 19. Brvar M, Fokter N, Bunc M, Mozina M. The frequency of adverse drug reaction related  
23 admissions according to method of detection, admission urgency and medical department  
24 specialty. *BMC Clinical Pharmacology* 2009, 9:8

25 20. Zopf Y, Rabe C, Neubert A, Hahn EG, Dormann H. Risk factors associated with adverse  
26 drug reactions following hospital admission: a prospective analysis of 907 patients in two  
27 German university hospitals. *Drug Saf.* 2008;31:789-98.

28 21. Camargo AL, Cardoso Ferreira MB, Heineck I. Adverse drug reactions: a cohort study in  
29 internal medicine units at a university hospital. *Eur J Clin Pharmacol.* 2006;62:143-9.

30 22. Fattinger K, Roos M, Vergères P, et als. Epidemiology of drug exposure and adverse drug  
31 reactions in two swiss departments of internal medicine. *Br J Clin Pharmacol.* 2000;49:158-67

32 23. Bond CA. Raehl CL. Adverse Drug Reactions in United States Hospitals. *Pharmacotherapy,*  
33 2006;26:601-608

34 24. Bates DW, Cullen DJ, Laird N, et als. Incidence of adverse drug events and potential drug  
35 events. Implications for prevention. *JAMA.* 1995;274:29-34.

36 25. Flockhart, D. A. Drug Interactions and Cytochrome P450 System: The role of Cytochrome  
37 P450 2C19. *Clin. Pharmacokinet.* 1995;29(suppl. 1): 45-52

38 26. Szekendi MK, Sullivan C, Bobb A et al. Active surveillance using electronic triggers to detect  
39 adverse events in hospitalized patients. *Qual Saf Health Care* 2006;15:184–190.

40 27. Bobb A, Gleason K, Husch M, et als. The epidemiology of prescribing errors: the potential  
41 impact of computerized prescriber order entry. *Arch Intern Med.* 2004;164:785-92.

42 28. Helldén A, Bergman U, von Euler M, et als. Adverse drug reactions and impaired renal  
43 function in elderly patients admitted to the emergency department: a retrospective study. *Drugs*  
44 *Aging.* 2009;26:595-606  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 29. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with  
4 renal dysfunction. Eur J Clin Pharmacol. 2009;65:757-73.

5  
6 30. Lundkvist J, Jönsson B. Pharmacoeconomics of adverse drug reactions. Fundam Clin  
7 Pharmacol. 2004;18:275-80.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

20  
21 **Fig 1: Distribution of patients according to presence of adverse drug reactions (ADRs)**




Table 1: Baseline Characteristics of Patients.

VARIABLE	CONTROL N=279	CASES N=126	p value
Sex-male	151(54%)	59(47%)	0.22
Age-years: median (range)	67(15-102)	69(16-97)	0.3
Age > 75 year- n(%)	112(40%)	53(42%)	0.25
Body Mass Index-Kg/m <sup>2</sup>	26±5	27±6	0.09
Previous Diagnosis	2.0±1.1	2.3±1.2	0.02
Chronic Heart Failure	98(35%)	54(43%)	0.1
Pulmonary Disorders	70(25%)	44(35%)	0.03
Diabetes	56(20%)	44(35%)	<0.001
Cardiovascular Diseases	64(23%)	30(24%)	0.4
Neuro-psychiatric disorders	45(16%)	16(13%)	0.3
Cancer	47(17%)	13(10%)	0.09
Chronic Renal Insufficiency	31(11%)	16(13%)	0.3
Liver disorders	28(10%)	15(12%)	0.3
Others diseases	123(44%)	59(47%)	0.3
Number of Drugs	4.6±3.2	5.0±2.4	0.2
Days of Hospital stay	9.6±5.8	18±17	<0.001
Time of ADR from hospitalization- days		4.3±3.9	

Table 2: Description of Adverse Drug Reactions, leading or occurred during hospitalization.

Event	Number of cases	Drug(number of cases)
<b>Gastrointestinal.-44(34%)</b>		
Diarrhea	28	Levofloxacin(17), ciprofloxacin(4), Amoxicilin/clavulanic(5), Ceftriaxone(1), Piperacillin/Tazobactam(1),
Pseudomenbranous colitis	2	Fosfomicine(1),Metformin(3),Chloroquin(1), colchicine(1),Levofloxacin(2)
Nausea/vomits	14	Digoxin(4),Rifampin(1), Vibramycin(1),Ceftazidime(2), sildenafil(1)
<b>Hematological -17(13%)</b>		
Bleeding,	15	Acenocumarol (11), Enoxaparin(4)
Thrombocytopenia	1	Heparin (1)
Pancytopenia	1	Ceftriaxone(1)
<b>Neurological and psychiatric-14(11%)</b>		
Oversedation	3	Fentanyl(1), tramadol(1), lorazepan(1)
Altered mental status	5	Zolpidem(2), lorazepan(1), litium(1), levofloxacin(1).
Dystonia /dyscinesias	3	Clebotrid(2)LevomEPROMAZIN(1)
Hallucinations	2	Pregalabalin(1), codein(1)
Seizures	1	Imipenem(1)
<b>Skin and mucosa.- 18(14%)</b>		
Rash	9	Ceftriaxon(3), Piperacillin/Tazobactam(1), levofloxacin(1), Phenitoin(2), atorvastatin(1),ciprofloxacin(1)
Steven Johnson	1	Trimetoprim/sulfametoxazol(1)
Muguet	8	Levofloxacin(4),meronem(1), budesonide(3)
<b>Hepatobiliary-8(6.2%)</b>		
Hepatitis	5	Amoxicilin/clavulanic(2), dexketoprophen(1), ciprofloxacin(1), enoxaparin(1)
Cholestasis	3	Salazopirin(1),etinilestradiol(1),rifampin(1)
<b>Cardiovascular- 7(5.5%)</b>		
Bradychardia	5	Digoxin(5)
Hypotension	2	Carvedilol(1), metamizol(1)
<b>Renal- 3(2.3%)</b>		
Renal dysfunction	3	Vancomicin(1), Iodure contrast(1),captopril(1)
<b>Electrolyte disorders-8(6.2%)</b>		
Hypokalemia	4	Hidroclorothiazid(4)
Hyponatremia	2	Duloxetin(1), furosemid(1)
Hyperkalemia	2	Spirolacton(2)
<b>Endocrine-3(2.3%)</b>		
Hypoglycemia	2	Glibenclamid(2)
Ginecomasty	1	Spirolacton(1)
<b>Respiratory-2(1.6%)</b>		
Cough	1	Enalapril(1)
Hipercapnic encephalopathy	1	Diazepan(1)
<b>Systemic-4(3.1%)</b>		
Fever	3	Ceftazidime(1), ciprofloxacin(1),plasma(1)
DRESS	1	Salazopirin(1)

DRESS: Drug Related Eosinophyllia with Sistemic Symptoms



Table 3: Differences in Patients with and without an Adverse Drug Reaction observed during hospitalization.

	CONTROL N=279	CASE N=102	p value
Use of more 5 drugs	173(62%)	67(66%)	0.38
Renal status at admission			
Serum creatinine-mg/dL.	1.11±0.57	1.28±0.78	<0.05
EGFR - (ml/min)	70.3±31.8	66.4±36.5	0.31
At ADR (case) or higher during hospitalization (control)			
Serum creatinine-mg/dL.	1.72±0.95	2.02±1.22	<0.05
EGFR <60 ml/m-(%)	61(22%)	42(41%)	<0.001
Change EGFR vs previous>20% -(%)	50(18%)	36(35%)	<0.001
Liver status			
Cirrhosis	22(8%)	12(12%)	0.24
ALT-UI/ml	73±43	81±79	0.21
FA- UI/ml	94±64	88±52	0.39
Albumin < 3 mg/dl-(%)	59(21%)	18(18%)	0.45
Number Drug with interaction(Grade>C)*			
0	179(64%)	16(16%)	<0.0001
Any	100(36%)	86(84%)	<0.0001
1-3	56(20%)	50(49%)	<0.0001
>3	45(16%)	36(35%)	<0.001
Medication use with interaction			
Cytochrome P450 2C19			
Inducer	1(0.4%)	2(1.9%)	0.12
Inhibitors	4(1.4%)	2(1.9%)	0.71
Substrates	4(1.4%)	3(2.9%)	0.68
Cytochrome P450 2C9			
Inducer	0	1(0.9%)	0.09
Inhibitors	18(6.4%)	14(13.7%)	<0.05
Substrates	13(4.7%)	14(13.7%)	<0.01
Cytochrome P450 3A4			
Inducer	1(0.4%)	4(3.9%)	<0.05
Inhibitors	7(2.5%)	6(5.8%)	0.11
Substrates	7(2.5%)	10(9.8%)	0.01
Cytochrome P450 2D6			
Inhibitors	5(1.8%)	5(4.9%)	0.09
Substrates	4(1.4%)	5(4.9%)	<0.05
Cytochrome P450 1A2			
Inhibitors	1(0.4%)	1(0.9%)	0.46
Substrates	2(0.7%)	2(1.9%)	0.29
Glycoprotein-P			
Inhibitors	2(0.7%)	2(1.9%)	0.29
Substrates	1(0.4%)	1(0.9%)	0.46
Change EGFR>20% or Drug interactions	131(47%)	90(88%)	<0.0001

EGFR: Estimated glomerular filtration rate \*: Grade >C denote interaction between drugs from a clinically significant manner to agents considered contraindicated (for more details see Methods)

Table 4: Logistic regression analysis with ADRs observed during hospitalization as dependent variable.

	<b>Odds ratio</b>	<b>95% CI</b>	<b>p value</b>
<b>Male</b>	0.94	0.59-1.51	0.81
<b>&gt;70 years</b>	1.37	0.84-2.26	0.21
<b>Treatment with more 5 drugs</b>	1.18	0.72-1.94	0.51
<b>More 12-days hospitalization</b>	2.11	1.27-3.47	<0.001
<b>Albumin &lt; 3 mg/dL</b>	1.22	0.74-2.05	0.49
<b>Any drug interaction (Grade&gt; C)</b>	9.33	5.12-17	<0.0001
<b>Change EFG &lt;20% over previous</b>	2.46	1.45-4.2	0.001

EGFR: Estimated glomerular filtration rate \*: Grade >C denote interaction between drugs from a clinically significant manner to agents considered contraindicated (for more details see Methods)